Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CAD Risk in Schizophrenia: Effect of Omega-3 Fatty Acid Supplementation

NCT00167310 is registered in ClinicalTrials.gov with University of Pittsburgh as lead sponsor.

NCT NCT00167310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00167310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CAD Risk in Schizophrenia: Effect of Omega-3 Fatty Acid Supplementation
Lead sponsor
University of Pittsburgh
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2005
Completion date
December 31, 2015
Enrollment
57 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder, coronary artery disease, major depression, schizoaffective disorder, schizophrenia